RhoVac AB participates in two international conferences and in an investor meeting in Sweden.
RhoVac AB ("RhoVac") announced today that the company will be presenting at Aktiesprarnas Aktiefrukost in Stockholm, Sweden and at 3rd Annual Advances in Immuno Oncology Congress, London, UK. In June, RhoVac will attend the International Convention, Boston, USA.
RhoVac's CEO Anders Ljungqvist will present status and plans for the company's drug candidate RV001 at Aktiespararnas Aktiefrukost, Operatorrassen, Stockholm, Sweden May 3, 2018. Registration for this event is via https://www.aktiespararna.se/aktiviteter/aktiefrukost-stockholm-3-maj.
Anders Ljungqvist will attend 3rd Annual Advances in Immuno-Oncology Congress 24-25 May 2018 in London, UK (https://www.immunooncology-congress.com/). Not only research institutes, but also global pharmaceutical companies and biotechnology companies are attending this conference.
RhoVac will also attend the Biotechnology Innovation Organization's (BIO) Conference International Convention, Boston, USA, between 4-7 June 2018. At BIO more than 1100 biotechnology companies, academic institutions and other related organizations from USA and over 30 other countries are represented.
For more information, please contact:
Anders Ljungqvist – CEO, RhoVac AB
Phone: +45 4083 2365
About RhoVac AB
RhoVac AB conducts research and development of immunotherapeutic drugs. The company's main focus is the development of a therapeutic cancer vaccine with the potential to prevent or limit metastasis in cancer. RhoVac's first drug candidate has completed pre-clinical phase and clinical phase I / II study has started spring 2017. RhoVac has its head office at Medicon Village in Lund, Sweden. The research has been conducted since 2007 primarily at the University Hospital in Herlev, Denmark, by a world-class research team in its niche. RhoVac is listed on AktieTorget, Sweden, a Multilateral Trading Facility (MTF), since March 2016. The share is traded under the ticker RHOVAC. Read more at www.rhovac.com